during hospitalisation, surgery or acute illness), in underweight people or when the diagnosis of type 1 diabetes is suspected
Weekly Injectable Formulations: Semaglutide (Ozempic) for type 2 diabetes typically starts at 0.25 mg once weekly for four weeks, then increases to 0.5 mg weekly
After 180 days, the primary outcome which included time to death, time to rehospitalization for heart failure, and time-averaged proportional change in NT-proBNP levels from baseline was not different between groups
The FDAs decision limits the disputed risks but does not address the gastrointestinal and vision injury allegations fueling the current litigation
[DOI] [PMC free article] [PubMed] [Google Scholar] 142.Ferrer-Garcia JC, Martinez-Chanza N, Tolosa-Torrens M, Sanchez-Juan C